Skip to content
Back to outputs

The Ellipta® in asthma and chronic obstructive pulmonary disease: device characteristics and patient acceptability

Research output: Contribution to journalArticle

Standard

The Ellipta® in asthma and chronic obstructive pulmonary disease : device characteristics and patient acceptability. / Jones, Thomas L.; Neville, Daniel M.; Chauhan, Anoop J.

In: Therapeutic Delivery, Vol. 9, No. 3, 02.2018, p. 169-176.

Research output: Contribution to journalArticle

Harvard

APA

Vancouver

Author

Bibtex

@article{c633b4a590ef49f8b77dd76f7b1d73d8,
title = "The Ellipta{\textregistered} in asthma and chronic obstructive pulmonary disease: device characteristics and patient acceptability",
abstract = "Asthma and chronic obstructive pulmonary disease are primarily treated with inhaled medication, but delivery of that medication to its site of action is problematic; patients{\textquoteright} ability to use inhalers will affect therapeutic response. Multiple inhaler devices are available but they are variably easy to use with consequent effects on compliance, intentional or otherwise. The Ellipta{\textregistered} device is a novel blister strip dry powder inhaler with medium resistance and a consistent delivered dose across a range of inspiratory flow rates. The Ellipta has proven easy to use and is preferred by patients across several evaluations and compared with other inhaler devices. The Ellipta is used to administer multiple inhaled medications, all in single daily-dose regimens, making it ideal for patients who struggle with complex inhaled therapy regimens.",
author = "Jones, {Thomas L.} and Neville, {Daniel M.} and Chauhan, {Anoop J.}",
year = "2018",
month = feb,
doi = "10.4155/tde-2017-0103",
language = "English",
volume = "9",
pages = "169--176",
journal = "Therapeutic Delivery",
issn = "2041-5990",
publisher = "Future Science",
number = "3",

}

RIS

TY - JOUR

T1 - The Ellipta® in asthma and chronic obstructive pulmonary disease

T2 - device characteristics and patient acceptability

AU - Jones, Thomas L.

AU - Neville, Daniel M.

AU - Chauhan, Anoop J.

PY - 2018/2

Y1 - 2018/2

N2 - Asthma and chronic obstructive pulmonary disease are primarily treated with inhaled medication, but delivery of that medication to its site of action is problematic; patients’ ability to use inhalers will affect therapeutic response. Multiple inhaler devices are available but they are variably easy to use with consequent effects on compliance, intentional or otherwise. The Ellipta® device is a novel blister strip dry powder inhaler with medium resistance and a consistent delivered dose across a range of inspiratory flow rates. The Ellipta has proven easy to use and is preferred by patients across several evaluations and compared with other inhaler devices. The Ellipta is used to administer multiple inhaled medications, all in single daily-dose regimens, making it ideal for patients who struggle with complex inhaled therapy regimens.

AB - Asthma and chronic obstructive pulmonary disease are primarily treated with inhaled medication, but delivery of that medication to its site of action is problematic; patients’ ability to use inhalers will affect therapeutic response. Multiple inhaler devices are available but they are variably easy to use with consequent effects on compliance, intentional or otherwise. The Ellipta® device is a novel blister strip dry powder inhaler with medium resistance and a consistent delivered dose across a range of inspiratory flow rates. The Ellipta has proven easy to use and is preferred by patients across several evaluations and compared with other inhaler devices. The Ellipta is used to administer multiple inhaled medications, all in single daily-dose regimens, making it ideal for patients who struggle with complex inhaled therapy regimens.

U2 - 10.4155/tde-2017-0103

DO - 10.4155/tde-2017-0103

M3 - Article

VL - 9

SP - 169

EP - 176

JO - Therapeutic Delivery

JF - Therapeutic Delivery

SN - 2041-5990

IS - 3

ER -

ID: 8871005